Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

M.K. Greene; T. Chen; E. Robinson; N.L. Straubinger; C. Minx; D.K.W. Chan; J. Wang; J.F. Burrows; S. Van Schaeybroeck; J.R. Baker; S. Caddick; D.B. Longley; D.E. Mager; R.M. Straubinger; V. Chudasama; C.J. Scott

doi:10.1038/s41416-020-01046-6

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

M.K. Greene
, T. Chen
, E. Robinson
, N.L. Straubinger
, C. Minx
, D.K.W. Chan
, J. Wang
, J.F. Burrows
, S. Van Schaeybroeck
, J.R. Baker
, S. Caddick
, D.B. Longley
, D.E. Mager
, R.M. Straubinger
, V. Chudasama
, C.J. Scott

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

212 Downloads (Pure)

Original language	English
Journal	British Journal of Cancer
DOIs	https://doi.org/10.1038/s41416-020-01046-6
Publication status	Published - 11 Sept 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41416-020-01046-6Licence: Unspecified

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
Copyright 2020 Springer. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 11.5 MBLicence: Unspecified

Cite this

Greene, M. K., Chen, T., Robinson, E., Straubinger, N. L., Minx, C., Chan, D. K. W., Wang, J., Burrows, J. F., Van Schaeybroeck, S., Baker, J. R., Caddick, S., Longley, D. B., Mager, D. E., Straubinger, R. M., Chudasama, V., & Scott, C. J. (2020). Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-020-01046-6

@article{0d4ad388058347e3950cf49b84ec782a,

title = "Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer",

author = "M.K. Greene and T. Chen and E. Robinson and N.L. Straubinger and C. Minx and D.K.W. Chan and J. Wang and J.F. Burrows and \{Van Schaeybroeck\}, S. and J.R. Baker and S. Caddick and D.B. Longley and D.E. Mager and R.M. Straubinger and V. Chudasama and C.J. Scott",

year = "2020",

month = sep,

day = "11",

doi = "10.1038/s41416-020-01046-6",

language = "English",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

}

Greene, MK, Chen, T, Robinson, E, Straubinger, NL, Minx, C, Chan, DKW, Wang, J, Burrows, JF , Van Schaeybroeck, S, Baker, JR, Caddick, S, Longley, DB, Mager, DE, Straubinger, RM, Chudasama, V & Scott, CJ 2020, 'Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer', British Journal of Cancer. https://doi.org/10.1038/s41416-020-01046-6

TY - JOUR

T1 - Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

AU - Greene, M.K.

AU - Chen, T.

AU - Robinson, E.

AU - Straubinger, N.L.

AU - Minx, C.

AU - Chan, D.K.W.

AU - Wang, J.

AU - Burrows, J.F.

AU - Van Schaeybroeck, S.

AU - Baker, J.R.

AU - Caddick, S.

AU - Longley, D.B.

AU - Mager, D.E.

AU - Straubinger, R.M.

AU - Chudasama, V.

AU - Scott, C.J.

PY - 2020/9/11

Y1 - 2020/9/11

U2 - 10.1038/s41416-020-01046-6

DO - 10.1038/s41416-020-01046-6

M3 - Article

SN - 0007-0920

JO - British Journal of Cancer

JF - British Journal of Cancer

ER -